[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xi'an Jiaotong University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":168},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,66,90,115,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100643665","the-effect-of-low-level-tragus-stimulation-on-inflammation-and-early-recurrence-after-pulsed-field-ablation-a-randomized-controlled-study-100643665",false,"NCT07633431","The Effect of Low-Level Tragus Stimulation on Inflammation and Early Recurrence After Pulsed Field Ablation: A Randomized Controlled Study","Inclusion Criteria:\n\n1. Age 18 to 80 years, inclusive.\n2. Diagnosed with paroxysmal or persistent atrial fibrillation by electrocardiogram or ambulatory electrocardiogram, and scheduled to undergo first catheter ablation for atrial fibrillation.\n3. Able to understand and sign the written informed consent form, and willing to participate in this study.\n4. Willing and able to comply with the follow-up requirements specified in the study protocol.\n\nExclusion Criteria:\n\n1. History of two or more previous catheter ablation procedures for atrial fibrillation.\n2. Scheduled to undergo concomitant cardiac surgery or other interventional procedures during the index procedure.\n3. History of cervical vagus nerve injury, abnormal ear anatomy, skin lesions, or other conditions that may prevent correct placement or tolerance of the auricular vagus nerve stimulation electrode.\n4. Left ventricular ejection fraction less than 40%.\n5. New York Heart Association functional class III or IV.\n6. Severe hepatic or renal dysfunction, defined as alanine aminotransferase or aspartate aminotransferase greater than two times the upper limit of normal, or estimated glomerular filtration rate less than 30 mL\u002Fmin\u002F1.73 m².\n7. Known inflammatory disease, connective tissue disease, active infection, or long-term use of glucocorticoids, non-steroidal anti-inflammatory drugs, or immunosuppressive agents for more than 4 weeks.\n8. Acute myocardial infarction or unstable angina within 3 months before enrollment.\n9. Percutaneous coronary intervention or coronary artery bypass grafting within 3 months before enrollment.\n10. Stroke or transient ischemic attack within 3 months before enrollment.\n11. Severe uncontrolled hypertension, defined as resting systolic blood pressure of 180 mmHg or higher, or resting diastolic blood pressure of 110 mmHg or higher.\n12. Sick sinus syndrome, second-degree type II atrioventricular block, or third-degree atrioventricular block without implantation of a permanent pacemaker.\n13. Pregnancy, lactation, or planned pregnancy during the study period.\n14. Participation in another drug or medical device clinical trial within 3 months before enrollment.\n15. Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study, such as expected survival less than 1 year or poor compliance.","ALL","18 Years","80 Years",{"count":19,"type":20},46,"ESTIMATED","INTERVENTIONAL",[23],"NA","Atrial fibrillation is a common heart rhythm disorder. Some patients may have early episodes of atrial arrhythmia after pulsed field ablation, and inflammation after the procedure may be related to these early episodes. Low-level tragus stimulation is a non-invasive form of nerve stimulation applied to the outer ear. It may help regulate the autonomic nervous system and inflammatory responses.\n\nThis randomized controlled study will evaluate whether low-level tragus stimulation after pulsed field ablation can reduce post-procedural inflammation and early atrial arrhythmia recurrence in patients with atrial fibrillation. Participants who meet the study criteria will be randomly assigned to receive either active low-level tragus stimulation or sham stimulation after the ablation procedure. The study will compare inflammatory markers before and after the procedure, monitor heart rhythm during and after the stimulation period, and assess early atrial arrhythmia recurrence during follow-up.\n\nThe investigators hypothesize that low-level tragus stimulation may reduce inflammatory responses after pulsed field ablation and may be associated with fewer early atrial arrhythmia episodes compared with sham stimulation.",[26],"Atrial Fibrillation","NOT_YET_RECRUITING","2026-06-03",{"date":30,"type":31},"2026-06-08","ACTUAL",{"date":33,"type":20},"2026-06-30",{"date":35,"type":20},"2027-12-30",{"name":37,"class":38},"Xi'an Jiaotong University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100635356","research-on-deep-learning-based-intelligent-diagnosis-and-treatment-100635356","NCT07551622","Research on Deep Learning-Based Intelligent Diagnosis and Treatment","Research on Intelligent Diagnosis and Treatment Technologies for Craniomaxillofacial Multi-modal Imaging Based on Deep Learning","Inclusion Criteria:\n\n* Participants with available craniomaxillofacial imaging data obtained during routine dental, orthodontic, oral and maxillofacial, or related clinical care.\n* Participants with at least one eligible imaging modality, including two-dimensional facial photographs, cone-beam computed tomography images, or three-dimensional facial surface scans.\n* Participants with related clinical information available for model development or validation, such as demographic information, clinical diagnosis, skeletal or dental classification, cephalometric measurements, treatment-related records, or expert assessment results.\n* Imaging data of sufficient quality for artificial intelligence-based image analysis, annotation, segmentation, landmark detection, classification, or decision-support model development.\n\nExclusion Criteria:\n\n* Participants with incomplete or unavailable key imaging data or clinical information required for the planned analysis.\n* Images with severe artifacts, poor resolution, incorrect orientation, incomplete anatomical coverage, or other quality problems that prevent reliable analysis.\n* Duplicate records or repeated imaging records that cannot be reliably linked to a unique participant.\n* Participants whose data cannot be used according to institutional review board approval, consent requirements, or applicable privacy protection regulations.",true,"6 Years","70 Years",{"count":51,"type":20},2000,"OBSERVATIONAL","This study aims to develop and evaluate deep learning-based artificial intelligence models for craniomaxillofacial multi-modal imaging analysis and clinical decision support. Approximately 2,000 participants with craniomaxillofacial imaging data and related clinical information will be included. The imaging data may include two-dimensional facial photographs, cone-beam computed tomography images, and three-dimensional facial surface scans.\n\nThe study will use artificial intelligence methods to analyze craniofacial images and identify clinically meaningful features related to facial morphology, skeletal or dental classification, anatomical landmarks, regional structures, and craniomaxillofacial abnormalities. The models will be developed for tasks such as image classification, anatomical landmark detection, image segmentation, abnormality recognition, and treatment-related decision support.\n\nThe purpose of this study is to improve the accuracy, efficiency, and consistency of image-based assessment in dentistry, orthodontics, and oral and maxillofacial clinical practice. The artificial intelligence models developed in this study are intended to provide objective imaging analysis and decision-support information for health care providers. These models are designed to assist clinicians and will not replace professional diagnosis or individualized treatment planning by qualified clinicians.\n\nThis research may benefit patients and families by supporting earlier and more accurate recognition of craniomaxillofacial conditions, improving communication about diagnosis and treatment options, and promoting more personalized oral health care. All clinical images and related information will be handled according to approved research procedures and privacy protection requirements.",[55,56,57],"Malocclusion","Craniofacial Morphology","Dentofacial Deformities","2026-04-19",{"date":60,"type":31},"2026-04-27",{"date":62,"type":20},"2026-05-01",{"date":64,"type":20},"2029-12-31",{"name":37,"class":38},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":47,"sex":15,"minAge":48,"maxAge":16,"enrollmentInfo":72,"targetDuration":74,"studyType":52,"phases":4,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100579453","orthodontic-treatment-on-oral-microbiota-and-salivary-proteins-100579453","NCT06824493","Orthodontic Treatment on Oral Microbiota and Salivary Proteins","Inclusion Criteria:\n\n* No carries and White spot\n* No missing teeth\n* No history of oral treatment\n* No malocclusion\n* No systemic diseases\n\nExclusion Criteria:\n\n* Antibiotic use in the past three months\n* A history of long-term medication use\n* A history of dental fillings\n* Unable to attend regular follow-ups",{"count":73,"type":20},150,"2 Years","Study on the changes in oral microbiota during orthodontic treatment in patients aged 8-18 years. Orthodontic patients treated at Stomatology Hospital of Xi'an Jiaotong University from March 2025 to March 2027 will be recruited. Prior to orthodontic treatment, routine preoperative examinations will be conducted, informed consent forms will be signed, baseline oral conditions will be recorded, and oral and psychological-related questionnaires will be completed. Patients will be informed of the need for regular oral hygiene check-ups, caries risk assessments will be performed, and plaque, saliva, and intraoral photographs will be collected. During orthodontic treatment, plaque samples will be collected every 3 months, and saliva samples will be collected every 6 months until the treatment is completed to evaluate the changes in oral microbiota throughout the orthodontic process.",[77,78,79],"Orthodontics","White Spot Lesions [Initial Caries] on Smooth Surface of Tooth","Caries, Dental",[81],"microbiota","2025-05-28",{"date":84,"type":31},"2025-06-04",{"date":86,"type":20},"2025-07-01",{"date":88,"type":20},"2027-09-01",{"name":37,"class":38},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":39},"100555854","disease-burden-and-living-situation-of-patients-with-facioscapulohumeral-muscular-dystrophy-100555854","NCT06517498","Disease Burden and Living Situation of Patients With Facioscapulohumeral Muscular Dystrophy","Inclusion Criteria:\n\n* Having been diagnosed as Facioscapulohumeral Muscular Dystrophy\n\nExclusion Criteria:\n\n* No",{"count":97,"type":20},300,"The goal of this observational study is to learn the patient journey, disease burden, living situation, quality of life and etc. in patients with Facioscapulohumeral Muscular Dystrophy in all sex\u002Fgender and age groups. The main questions it aims to answer are:\n\n1. What's the patient journey of patients with Facioscapulohumeral Muscular Dystrophy?\n2. How does Facioscapulohumeral Muscular Dystrophy burden the patients?\n3. How's the quality of life of patients with Facioscapulohumeral Muscular Dystrophy?\n\nPatients with Facioscapulohumeral Muscular Dystrophy will be asked to:\n\n1. fill a questionnaire.\n2. be interviewed and answer questions about their illness experience, economic burden, quality of life and etc.\n\nMedical experts on Facioscapulohumeral Muscular Dystrophy will be asked to be interviewed and answer questions about understanding on the disease and the patients.",[100],"Muscular Dystrophy, Facioscapulohumeral",[102,103,104,105],"Facioscapulohumeral Muscular Dystrophy","Disease Burden","Quality of Life","Living Situation","RECRUITING","2024-07-18",{"date":109,"type":31},"2024-07-24",{"date":111,"type":31},"2024-03-01",{"date":113,"type":20},"2025-07",{"name":37,"class":38},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":39},"100544375","phase-4-the-study-of-huaier-granule-in-postoperative-adjuvant-therapy-of-resectable-pancreatic-cancer-100544375","NCT06368063","The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer","Study on the Efficacy and Safety of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer","Inclusion Criteria:\n\n* Age range from 18 to 80 years old, regardless of gender;\n* Pancreatic cancer was diagnosed by histopathology after radical surgery within 12 weeks before enrollment;\n* Did not receive neoadjuvant therapy before surgery and did not receive any adjuvant therapy after surgery;\n* ECOG score 0-3 points;\n* Those who choose to use standard chemotherapy independently based on their own situation, or choose Huaier granules for subsequent treatment, voluntarily participate in and cooperate with various research work, including but not limited to cooperating with treatment and follow-up, cooperating with researchers for data collection, and not actively taking other treatments.\n* The subjects voluntarily signed a written informed consent form before participating in this study.\n\nExclusion Criteria:\n\n* Known to be allergic to the components of Huaier granules or to avoid or use Huai er granules with caution (Huaier group);\n* Difficulties in taking oral medication due to active gastrointestinal bleeding, perforation, gastric paralysis, etc;\n* Suffering from serious mental illness or other reasons that the researcher deems unsuitable to participate in this study.\n* History of merging with other malignant tumors;\n* Patients with concomitant myocardial infarction, cerebral infarction, and other thromboembolic diseases requiring surgical treatment;\n* Concomitant severe infection;\n* Child Pugh C-grade liver function, renal function 2-5 grades (glomerular filtration rate\\\u003C90ml\u002Fmin);\n* Pregnant or lactating women or those planning to conceive;\n* The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect, chemotherapy or physical therapy in the past 4 weeks(including but not limited to compound cantharidin capsules, cinobufotalin capsules, Kangai injection, please refer to the drug instructions for details).",{"count":123,"type":20},642,[125],"PHASE4","The study is a multicenter, prospective clinical study aimed at evaluating the efficacy and safety of Huaier Granule in postoperative adjuvant treatment of resectable pancreatic cancer",[128],"Pancreatic Cancer Resectable",[130,131,132,133],"Huaier granule","Postoperative adjuvant therapy","Resectable pancreatic cancer","Efficacy and safety","2024-05-07",{"date":136,"type":31},"2024-05-08",{"date":138,"type":31},"2024-05-06",{"date":140,"type":20},"2028-03",{"name":37,"class":38},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":4},"100545857","phase-4-clinical-study-of-huaier-granule-in-the-treatment-of-unresectable-pancreatic-cancer-100545857","NCT06387368","Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer","Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study on the Efficacy and Safety of Huaier Granules Combined With Capecitabine Versus Capecitabine Alone in the Treatment of Unresectable Pancreatic Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years old, regardless of gender.\n* The patient has a clear evaluable lesion (RECIST 1.1) and is diagnosed with pancreatic adenocarcinoma through tissue or cellular pathology. Clinical evaluation suggests that radical surgical resection cannot be performed (due to jaundice and gastrointestinal obstruction caused by tumor compression, stent treatment or normal inclusion of biliary and gastrointestinal anastomosis can be performed).\n* Patients voluntarily give up conversion therapy, local radiation therapy, targeted immunity, and other programs.\n* The patient voluntarily choose chemotherapy, and the plan is to take capecitabine monotherapy orally.\n* ECOG score 0-3 points.\n* The patients voluntarily participate in and cooperates with all aspects of the research, including but not limited to cooperating with treatment and follow-up, cooperating with the researcher in data collection, not actively taking other treatments, and signing a written informed consent form.\n\nExclusion Criteria:\n\n* Known to be allergic to the components of Huaier granules or to avoid or use Huaier granules with caution (Huaier group).\n* Patients with difficulty swallowing, complete or incomplete gastrointestinal obstruction (excluding those who have undergone gastrointestinal stenting or diversion surgery due to tumor related gastrointestinal obstruction and have a normal diet, can be included in the study normally), active gastrointestinal bleeding, perforation, and other oral medication difficulties.\n* After actively reducing jaundice (including but not limited to bile duct\u002Fgallbladder puncture external drainage, nasobiliary duct external drainage, biliary stent internal drainage, biliary intestinal anastomosis internal drainage, etc.), the levels of aspartate aminotransferase, alanine aminotransferase, or total bilirubin are still 2.5 times higher than the upper limit of normal values.\n* History of merging with other malignant tumors.\n* Patients with concomitant myocardial infarction, cerebral infarction, and other thromboembolic diseases requiring surgical treatment.\n* Concomitant severe infection.\n* Child-Pugh C-grade liver function, renal function 2-5 grades (glomerular filtration rate\\\u003C90ml\u002Fmin).\n* Pregnant or lactating women or those planning to conceive.\n* The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect, chemotherapy or physical therapy in the past 4 weeks(including but not limited to compound cantharidin capsules, cinobufotalin capsules, Kangai injection, please refer to the drug instructions for details).\n* Suffering from serious mental illness or other reasons that the researcher deems unsuitable to participate in this study.",{"count":150,"type":20},488,[125],"This is a prospective, multicenter, randomized, open, parallel controlled clinical study to evaluate the efficacy and safety of Huaier Granules combined with capecitabine in the treatment of unresectable pancreatic cancer.",[154],"Pancreatic Cancer Non-resectable",[156,157,158,159],"Huaier Granules","Capecitabine","Unresectable Pancreatic Cancer","Efficacy and Safety","2024-04-23",{"date":162,"type":31},"2024-04-29",{"date":164,"type":20},"2024-05",{"date":166,"type":20},"2028-08",{"name":37,"class":38},""]